AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Kala Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference

May 7, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--May 7, 2019--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to provide a corporate overview on Tuesday, May 14, 2019 at 8:15 a.m. PT (11:15 a.m. ET).

To access a live webcast and subsequent archived recording of the presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYS™ for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) was accepted for review with the United States Food and Drug Administration (FDA) and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005058/en/

CONTACT: Investors:

Michael Schaffzin, 212-362-1200

michael.schaffzin@sternir.com

or

Media:

Kari Watson, 781-235-3060

kwatson@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEVADA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL FDA

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 05/07/2019 08:00 AM/DISC: 05/07/2019 08:00 AM

http://www.businesswire.com/news/home/20190507005058/en